White Paper: CRISPR/Cas9 Gene Editing
Enhanced Confidence in the Safety and Efficacy of CRISPR/Cas9 Gene Editing
Current approaches to characterizing CRISPR/Cas9-based cell and gene therapy candidates may miss off-target edits and correlated gene expression changes. Read our perspective on how emerging single-cell multiomics technologies put more comprehensive data in researchers' hands.
In this white paper, you'll read about:
- The range of on-target and off-target genomic and transcriptomic changes possible with CRISPR/Cas9 gene editing
- Why single-cell multiomic analysis is necessary to characterize and validate CRISPR/Cas9 therapeutic candidates
- Tools that make it possible to precisely, sensitively detect insertions, deletions, substitutions, larger genomic alterations, alternative splicing events, and altered gene expression across the entire genome – and attribute these variants to individual cells.